CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice-Reference-Cited by-同舟云学术

CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Van der Meer Jolien M.R.¹^ORCID,de Jonge Paul K.J.D.¹^ORCID,van der Waart Anniek B.¹^ORCID,Geerlings Alexander C.¹^ORCID,Moonen Jurgen P.¹,Brummelman Jolanda¹^ORCID,de Klein Janne¹,Vermeulen Malou C.¹,Maas Ralph J.A.¹^ORCID,Schaap Nicolaas P.M.²^ORCID,Hoogstad-van Evert Janneke S.¹³^ORCID,Ottevanger Petronella B.⁴^ORCID,Jansen Joop H.¹^ORCID,Hobo Willemijn¹^ORCID,Dolstra Harry¹^ORCID

Affiliation:

1. Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center/Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands

2. Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands

3. Department of Obstetrics and Gynecology, Amphia Hospital, The Netherlands

4. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands

Funder

Ruby & Rose foundation

Radboud Institute for Molecular Life Sciences

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1981049